Abera Bioscience is a Swedish biotechnology company that develops nasal vaccines based on a proprietary OMV-based platform technology. The company's focus is on nasal vaccines that provide immune responses in both mucosal and systemic areas. Abera develops vaccines against several respiratory infectious diseases, including pneumococci, influenza and pandemic preparedness, with projects in preclinical and planned clinical phases. The company was founded in 2012 and is headquartered in Uppsala.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 10,58 | 10,58 | 2026-03-27 |
| Göran Ofsen Dbo | 9,34 | 9,34 | 2026-03-27 |
| Nordnet Pensionsförsäkring | 6,79 | 6,79 | 2026-03-27 |
| Anders Ericsson | 3,04 | 3,04 | 2026-03-27 |
| Jan-Willem De Gier | 2,90 | 2,90 | 2026-03-27 |
| Joen Luirink | 2,85 | 2,85 | 2026-03-27 |
| Stefan Olsson | 2,60 | 2,60 | 2026-03-27 |
| Agneta Albinsson | 2,45 | 2,45 | 2026-03-27 |
| Maths Wahlström | 2,45 | 2,45 | 2026-03-27 |
| Martin Ericsson | 2,36 | 2,36 | 2026-03-27 |
2026-08-20 Interim Report 2026-Q2
2026-11-17 Interim Report 2026-Q3
2027-02-15 Year End Report 2026
